Skip to content

Evaluation of an IoT-baced respiratory rehabilitation program in pations with minimally invasive lobectomy :a prospective, single-center , randomized, open parallel clinical study

Evaluation of an IoT-baced respiratory rehabilitation program in pations with minimally invasive lobectomy :a prospective, single-center , randomized, open parallel clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123294
Enrollment
Unknown
Registered
2026-04-23
Start date
2024-09-05
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

intervention group :Respiratory Rehabilitation Group Based on Internet of Things:In addition to adopting Enhanced Recovery After Surgery (ERAS) nursing protocols, an IoT-based respiratory rehabilitati
control group:Respiratory Exercise Group:In addition to receiving enhanced recovery after surgery (ERAS) care, patients are provided with instructions on respiratory exercises. Postoperatively, they a

Sponsors

The First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 75 years old; 2. Planned minimally invasive unilateral lung resection surgery; 3. Preoperative lung function test shows that the measured FEV1 value is greater than or equal to 1.2L and greater than or equal to 60% of the expected value 4. Capable of using smart devices and filling out electronic questionnaires; 5. Clear consciousness, no reading, communication or cognitive impairment, and signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Smoking cessation time before surgery is less than 2 weeks; 2. Preoperative patient functional status score (ECOG score) is greater than 1 point; 3. Patients who have received preoperative neoadjuvant therapy; 4. Patients who have undergone chest surgery in the past; 5. There is evidence to suggest continuous use of systemic corticosteroids within one month prior to surgery; 6. At the beginning of the treatment study, any unresolved toxicity from previous treatments is greater than CTCAE grade 1; 7. Having a history of major illnesses in the past, including a history of other malignant tumors within 5 years, and a history of angina pectoris, myocardial infarction, and stroke within 6 months; 8. There is evidence to suggest the existence of serious or uncontrollable systemic diseases, including thyroid disease, uncontrolled hypertension, coagulation dysfunction, or active infections, such as hepatitis B, hepatitis C, and human immunodeficiency virus (HIV); 9. According to the researcher's judgment, there are other situations where the patient is not suitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Pulmonary function trajectory;

Secondary

MeasureTime frame
Satisfaction level;Adverse event incidence rate;quality of life;Symptom rating;

Countries

China

Contacts

Public ContactJieping Zhang

The First Affiliated Hospital of Zhejiang University School of Medicine

zjppxwk@zju.edu.cn+86 138 5710 8886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026